Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections.
The aim of the research was to study a new cidofovir/sucralfate drug product to be used as a spray for treating the mucosal and/or skin lesions. The product, i.e., a water suspension of sucralfate (15% w/w) and cidofovir (1% w/w), combines the potent antiviral activity of the acyclic nucleoside phosphonate cidofovir ((S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine) and the wound healing properties of sucralfate gel (sucrose octasulphate basic aluminum salt). The product was characterized in vitro with respect to compatibility between drug and carrier, spray particle size, spray deposition, drying kinetics, and drug content and release. An interaction between the two active substances was found. The interaction between sucralfate and cidofovir was counteracted by introducing sodium dihydrogen phosphate (16% w/w) in the preparation. The spray formulation containing cidofovir/sucralfate gel painted the skin and dried quickly to a scab, remaining firmly adhered to the lesions. The therapeutic paint was tested in vivo on lambs infected with orf virus by treating the animals with different cidofovir/sucralfate formulations (0.5% or 1% cidofovir + sucralfate 15% + NaH(2)PO(4) 16% w/w) and with sucralfate gel suspension alone as control. The treatment with formulations containing cidofovir and phosphate salt for four consecutive days resulted in a rapid resolution of the lesions, with scabs containing significantly lower amounts of viable virus when compared with untreated lesions and lesions treated with sucralfate suspension alone.
Sonvico
Fabio
F
Department of Pharmacy, University of Parma, Viale G.P. Usberti, 27/a, Parma, 43100, Italy.
Colombo
Gaia
G
Gallina
Laura
L
Bortolotti
Fabrizio
F
Rossi
Alessandra
A
McInnes
Colin J
CJ
Massimo
Gina
G
Colombo
Paolo
P
Scagliarini
Alessandra
A
D000287:Administration, Topical; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis / Q000302:isolation & purification; D004474:Ecthyma, Contagious / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D005079:Excipients; D005782:Gels; D009923:Orf virus; D063065:Organophosphonates / Q000008:administration & dosage* / Q000627:therapeutic use*; D010316:Particle Size; D033081:Shear Strength; D012756:Sheep; D012867:Skin / Q000473:pathology; D017550:Spectroscopy, Fourier Transform Infrared; D013392:Sucralfate / Q000008:administration & dosage* / Q000627:therapeutic use*
D000998:Antiviral Agents; D004279:DNA, Viral; D005079:Excipients; D005782:Gels; D063065:Organophosphonates; D013392:Sucralfate; D003596:Cytosine; D000077404:Cidofovir